CANF

CANF

USD

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

$1.130-0.035 (-3.038%)

Real-time Price

Healthcare
Biotechnology
Israel

Price Chart

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$1.165

High

$1.170

Low

$1.130

Volume

0.00M

Company Fundamentals

Market Cap

15.8M

Industry

Biotechnology

Country

Israel

Trading Stats

Avg Volume

0.29M

Exchange

ASE

Currency

USD

52-Week Range

Low $1.13Current $1.130High $4.69

Related News

GlobeNewswire

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and

View more
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Analyst Upgrades

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma with a Buy and maintains $10 price target.

View more
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
GlobeNewswire

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

View more
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
GlobeNewswire

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

View more
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
GlobeNewswire

Can-Fite Reports 2024 Financial Results and Clinical Update

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and

View more
Can-Fite Reports 2024 Financial Results and Clinical Update